Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. (Q37865505)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Richard Holt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Daniel J Walker

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Vicki Poole Hoffmann

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

455-482

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Nutritional assessment of patients with schizophrenia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Aripiprazole, a novel atypical antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine and haloperidol in first episode psychosis: two-year data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Differential effect of clozapine on weight: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Early predictors of substantial weight gain in bipolar patients treated with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine: interpreting the label change

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Schizophrenia after prenatal famine. Further evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Weight gain as a risk factor for clinical diabetes mellitus in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Metabolic syndrome and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Do guidelines for severe mental illness promote physical health and well-being?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Belgian consensus on metabolic problems associated with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Schizophrenia, obesity, and antipsychotic medications: what can we do?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Solutions for Wellness: Results of a Manualized Psychoeducational Program for Adults with Psychiatric Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589060-000000000-00000

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

21 January 2018

1 reference

12 December 2020

Pharmacogenetics of antipsychotic-induced side effects

1 reference

12 December 2020

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

1 reference

12 December 2020

Immunological characteristics of diabetes in schizophrenia

1 reference

12 December 2020

Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs

1 reference

12 December 2020

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

12 December 2020

Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group

1 reference

12 December 2020

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

1 reference

12 December 2020

The continuing increase of diabetes in the US

1 reference

12 December 2020

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

1 reference

12 December 2020

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

The unhealthy lifestyle of people with schizophrenia

1 reference

12 December 2020

Death by confounding: bias and mortality

1 reference

12 December 2020

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.

1 reference

12 December 2020

Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004.

1 reference

12 December 2020

Weight gain during treatment of bipolar I patients with olanzapine.

1 reference

12 December 2020

The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro.

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Obesity among adults in the United States--no statistically significant change since 2003-2004

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia

1 reference

12 December 2020

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

1 reference

12 December 2020

A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data.

1 reference

12 December 2020

The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

1 reference

12 December 2020

Metabolic disturbance in first-episode schizophrenia.

1 reference

12 December 2020

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

1 reference

12 December 2020

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

1 reference

12 December 2020

Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.

1 reference

12 December 2020

'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary.

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Stress and the genesis of diabetes mellitus in schizophrenia

1 reference

12 December 2020

SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?

1 reference

12 December 2020

Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.

1 reference

12 December 2020

Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.

1 reference

12 December 2020

Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients.

1 reference

12 December 2020

Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls

1 reference

12 December 2020

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia

1 reference

12 December 2020

10.2165/11589060-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21495734%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference